Optimal therapy of advanced ovarian cancer: Carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 149-155

  Bookman, Michael A ^a   Greer, B E ^b   Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Ovarian cancer; Paclitaxel; Second look

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND LOOK SURGERY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SECOND-LOOK SURGERY; SURVIVAL ANALYSIS;

EID: 1242297574     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13362.x     Document Type: Conference Paper

References (12)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
3. Bookman MA, McGuire WP, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902.
4. Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA et al. Carboplatin vs. cisplatin. Ann Oncol 1993;4:S41-8.
5. Ozols RF, Bundy BN, Fowler J et al. Randomized phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc Ann Meet Am Soc Clin Oncol 1999;18:A1373.
6. Ozols RF, Bundy BN, Greer BE et al. Paclitaxel and carboplatin compared to paclitaxel and cisplatin in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21:3194-20.
7. Greer BE, Bundy BN, Ozols RF et al. Implications of second-look laparotomy (SLL) in the context of Gynecologic Oncology Group (GOG) protocol 158: a non-randomized comparison using an explanatory analysis. Abstracts presented for the Thirty-Fourth Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 2003;88:156-261.
8. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
9. du Bois A, Lück HJ, Meier W et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynäkologie (AGO) Study Group Trial. Proc Ann Meet Am Soc Clin Oncol 1999;18:A1374.
10. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
11. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002;360:505-15.
12. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003;21: 149s-67s.